Clinical Trials Logo

Clinical Trial Summary

Individuals with spinal cord injury (SCI) are living to ages when metabolic disorders are highly prevalent. The combination of impaired glucose tolerance and insulin resistance can disrupt lipid metabolism and increase the risk of cardiovascular disease and diabetes, and contribute to an accelerated aging process in the SCI population. Feasible interventions to improve metabolic function in the chronic SCI are in great demand. Compared to pharmacologic therapies, dietary modification is a more cost-effective treatment option for reducing the risk of metabolic dysfunction that, surprisingly, has not been rigorously investigated in people with SCI. Therefore, in the present study the investigators will investigate the efficacy of an 8-week, eucaloric (a meal plan designed specifically to provide the exact amount of calories needed to maintain a given body weight) LC-HP dietary intervention for improving metabolic function, body composition, gut bacteria composition and quality of life in individuals with SCI and impaired glucose tolerance or type 2 diabetes. The investigators also aim to determine the association between changes in the composition of gut bacteria and improvements in metabolic function and the association between improvements in metabolic function and improvements in quality of life.


Clinical Trial Description

Individuals with spinal cord injury (SCI) are living to ages when metabolic disorders are highly prevalent. Due to the loss of mobility and severe skeletal muscle atrophy in individuals with SCI, obesity, impaired glucose tolerance, and peripheral insulin resistance develop after injury . The combination of impaired glucose tolerance and insulin resistance can disrupt lipid metabolism and increase the risk of cardiovascular disease and diabetes, and contribute to an accelerated aging process in the SCI population. Because of these trends, the overall burden of health complications and their economic impact has increased for individuals with SCI, often leading to a progressive decrease in their long-term quality of life. Feasible interventions to improve metabolic function (i.e. the way the body processes proteins, carbohydrates, and fats in foods) in those with chronic SCI are in great demand. Given that metabolic disorders severely compromise health outcomes and important domains of quality of life, including participation in daily life and community living and employment outcomes, targeted strategies to combat these morbidities are of paramount importance. Compared to pharmacologic therapies, dietary modification is a more cost-effective treatment option for reducing the risk of metabolic dysfunction that, surprisingly, has not been rigorously investigated in people with SCI. Much like the general U.S. population, individuals with SCI consume far more fat and carbohydrate than recommended levels. High fat, high carbohydrate diets (western diet) have been associated with a higher prevalence of obesity and metabolic disease as well as negative adaptations in the diversity of gut bacteria (increased levels of harmful bacteria and reduced levels of beneficial bacteria) that usually precedes the development of diabetes or insulin resistance. Therefore, macronutrient (carbohydrate, protein, and fat) modification may be able to prevent or correct the impaired metabolic state in persons with SCI. Diets composed of relatively high protein and low carbohydrate have been shown to improve body composition (i.e., reduce body fat while maintaining lean tissue) and metabolic profiles (i.e., increase in insulin sensitivity and glucose tolerance) in diabetic, able bodied individuals who are obese or overweight. This improvement is thought to be due to protein's: (i) effect on the sensation of feeling full after eating food despite similar or lower energy intake; (ii) contribution to storage of fat-free mass; and (iii) insulin sensitizing effect. The investigators' pilot work supports this hypothesis in that we showed that 8 weeks of a low carbohydrate/high-protein (LC-HP) diet significantly improved whole body insulin sensitivity (WBIS) and glucose tolerance and decreased the amount of intra-abdominal fat in six men with SCI and with either untreated type 2 diabetes or impaired glucose tolerance (pre-diabetes). In addition to significant improvements in metabolic health, our pilot work also successfully demonstrated the safety and feasibility of our approach. The lack of adverse effects and the improvement in glucose control and insulin sensitivity in our study participants with SCI prompted us to propose the current study involving both men and women in order to determine the effects of the dietary protocol to treat type 2 diabetes or impaired glucose tolerance in persons with chronic SCI. Thus, the investigators propose an investigation to determine if 8 weeks of an LC/HP dietary intervention induces the physiological adaptations necessary to improve metabolic function and body composition and alter the diversity of gut bacteria in a large cohort of individuals with SCI. The ultimate outcome of this project will be an effective diet program which can be easily and economically implemented at home as a non-pharmacological means of achieving blood glucose control for people with SCI and impaired glucose tolerance or untreated type 2 diabetes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03207841
Study type Interventional
Source Ohio State University
Contact
Status Completed
Phase N/A
Start date November 1, 2017
Completion date August 29, 2022

See also
  Status Clinical Trial Phase
Completed NCT05594446 - Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
Completed NCT03975309 - DHS MIND Metabolomics
Completed NCT01855399 - Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes N/A
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05007990 - Caregiving Networks Across Disease Context and the Life Course
Active, not recruiting NCT04420936 - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program N/A
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT04903496 - Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
Completed NCT01437592 - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects Phase 1
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT03390179 - Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Recruiting NCT05294822 - Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes N/A
Completed NCT04427982 - Dance and Diabetes/Prediabetes Self-Management N/A
Completed NCT02356848 - STEP UP to Avert Amputation in Diabetes N/A
Completed NCT03292185 - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects Phase 1
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4